Boothbay Fund Management, LLC Protagonist Therapeutics, Inc Transaction History

Boothbay Fund Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$14.05 - $23.44 $1.13 Million - $1.89 Million	80,607 New	80,607 $1.85 Million
Q2 2022 Aug 15, 2022	SELL	$7.06 - $25.52 $696,949 - $2.52 Million	-98,718 Reduced 63.02%	57,923 $458,000
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $3.66 Million - $5.65 Million	156,641 New	156,641 $3.71 Million
Q2 2020 Aug 14, 2020	SELL	$6.19 - $18.84 $142,611 - $434,054	-23,039 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$5.4 - $9.22 $54,788 - $93,546	10,146 Added 78.69%	23,039 $163,000
Q4 2019 Feb 14, 2020	SELL	$4.69 - $13.45 $169,210 - $485,262	-36,079 Reduced 73.67%	12,893 $91,000
Q3 2019 Nov 14, 2019	SELL	$9.41 - $16.56 $536,304 - $943,804	-56,993 Reduced 53.78%	48,972 $588,000
Q2 2019 Aug 14, 2019	BUY	$8.98 - $12.96 $951,565 - $1.37 Million	105,965 New	105,965 $1.28 Million
Q1 2019 May 15, 2019	SELL	$6.5 - $13.77 $129,460 - $274,257	-19,917 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$6.3 - $10.44 $125,477 - $207,933	19,917 New	19,917 $134,000

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.